Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
1.550
-0.070 (-4.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
51 Biggest Movers From Yesterday
February 09, 2022
Also check out this: Apple And 3 Other Stocks Sold By Insiders Losers SelectQuote, Inc. (NYSE: SLQT) shares tumbled 47.3% to close at $3.44 on Tuesday after the company...
Via
Benzinga
Editas Suddenly Terminates Chief Medical Officer Without An Explanation
February 08, 2022
Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.
Via
Benzinga
35 Stocks Moving In Tuesday's Mid-Day Session
February 08, 2022
Gainers Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) climbed 56.1% to $3.45 following...
Via
Benzinga
Analyst Ratings For Editas Medicine
October 19, 2021
Within the last quarter, Editas Medicine (NASDAQ:EDIT) has observed the fo...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 08, 2022
Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 7.8% to $1.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $59...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 08, 2022
Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
21 Stocks Moving in Tuesday's Pre-Market Session
February 08, 2022
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out this: Moderna And 4 Other Stocks Sold By...
Via
Benzinga
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
January 10, 2022
The companies hope to cure diseases of the liver, muscle and central nervous system.
Via
Investor's Business Daily
Stocks Hitting New 52-Week Lows Today
January 03, 2022
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...
Via
Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.
Via
InvestorPlace
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
December 13, 2021
Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR).
Via
InvestorPlace
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
December 13, 2021
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937.
Via
InvestorPlace
EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today
December 13, 2021
After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.
Via
InvestorPlace
22 Stocks Moving in Monday's Pre-Market Session
December 13, 2021
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose...
Via
Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
November 15, 2021
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
Via
Talk Markets
Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript
November 08, 2021
EDIT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Editas Medicine Stock Is Jumping Today
November 08, 2021
The gene-editing biotech company provided its Q3 update.
Via
The Motley Fool
Should You Scoop Up Shares of This Promising Biotech on the Dip?
October 28, 2021
This gene-editing specialist could still be an excellent long-term play.
Via
The Motley Fool
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful
October 19, 2021
EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:
Via
Benzinga
What's Hot in the Stock Market?
October 11, 2021
We've got a look at Merck and Amazon and Warby Parker and more.
Via
The Motley Fool
Exposures
COVID-19
12 Health Care Stocks Moving In Friday's Intraday Session
October 08, 2021
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...
Via
Benzinga
3 Spooky Healthcare Stocks I Would Avoid in October
October 07, 2021
Investors craving treats should look elsewhere this month.
Via
The Motley Fool
Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal
September 30, 2021
One of the leading CRISPR stock is under pressure on underwhelming data.
Via
Investor's Business Daily
52 Biggest Movers From Yesterday
September 30, 2021
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.